The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee on 10 December will be tasked with reviewing the available efficacy and safety data on Pfizer Inc./BioNTech SE’s COVID-19 vaccine.
However, given the unprecedented speed with which BNT162b2 was developed amid a pandemic that has killed more than 280,000 US residents, the panel’s attention also is likely to focus on what is not